Volume 23, Number 1—January 2017
Research
Sequelae and Other Conditions in Ebola Virus Disease Survivors, Sierra Leone, 2015
Table
Characteristic | Overall† | Fever‡ |
p value§ | |
---|---|---|---|---|
Yes | No | |||
Sex | ||||
M | 187 (30.7) [27.1–34.4] | 123 (30.2) | 64 (25.1) | 0.309 |
F |
423 (69.3) [65.6–72.9] |
284 (69.8) |
191 (74.9) |
Ref |
Duration since discharge, d | ||||
4–144 | 131 (21.1) [18.1–24.5] | 61 (14.8) | 107 (42.1) | <0.001 |
145–254 | 134 (21.6) [18.5–25.0] | 96 (23.4) | 69 (27.2) | <0.001 |
255–358 | 221 (35.6) [31.9–39.5] | 125 (30.4) | 41 (16.1) | 0.321 |
359–504 |
134 (21.6) [18.5–25.0] |
129 (31.4) |
37 (14.6) |
Ref |
Age, y | ||||
<18 | 153 (25.0) [21.7–28.5] | 109 (26.4) | 39 (15.1) | Ref |
18–28 | 148 (24.1) [20.9–27.7] | 86 (20.8) | 52 (20.1) | 0.178 |
29–35 | 153 (25.0) [21.7–28.5] | 142 (34.4) | 110 (42.5) | 0.025 |
36–70 | 159 (25.9) [22.6–29.6] | 76 (18.4) | 58 (22.4) | 0.010 |
Median (range) |
30.0 (0.25–70.00) |
30.0 (0.25–70.00) |
33.0 (3–70.00) |
0.001 |
Signs and symptoms¶ | ||||
Joint pain | 187 (30.1) [26.6–33.8] | 113 (29.5) | 74 (31.1) | 0.627 |
Myalgia | 269 (43.3) [39.5–47.3] | 165 (43.1) | 104 (43.7) | 0.874 |
Cough | 201 (32.4) [28.8–36.2] | 171 (44.7) | 30 (12.6) | <0.001 |
Weakness | 37 (6.0) [4.3–8.1] | 27 (7.1) | 10 (4.2) | 0.097 |
Dizziness | 89 (14.3) [11.8–17.3] | 55 (14.4) | 34 (14.3) | 0.915 |
Rash | 32 (5.2) [3.7–7.2] | 20 (5.2) | 12 (5.0) | 0.903 |
Itching | 49 (7.9) [6.0–10.3] | 24 (6.3) | 25 (10.5) | 0.028 |
Blurred vision | 19 (3.1) [2.0–4.8] | 8 (2.1) | 11 (4.6) | 0.034 |
Vision loss | 0 | 0 | 0 | NA |
Eye discharge | 12 (1.9) [1.1–3.4] | 5 (1.3) | 7 (2.9) | 0.097 |
Poor vision | 15 (2.4) [1.5–4.0] | 6 (1.6) | 9 (3.8) | 0.043 |
Eye pain | 10 (1.6) [0.9–3.0] | 7 (1.8) | 3 (1.3) | 0.837 |
Eye itch | 13 (2.1) [1.2–3.6] | 6 (1.6) | 7 (2.9) | 0.113 |
Eye irritation | 9 (1.4) [0.8–2.8] | 8 (2.1) | 1 (0.4) | 0.119 |
Eye problems | 51 (8.2) [6.3–10.7] | 29 (7.6) | 22 (9.2) | 0.205 |
Headache | 392 (63.1) [59.2–66.8] | 272 (71.0) | 120 (50.4) | <0.001 |
Diarrhea | 17 (2.7) [1.7–4.4] | 14 (3.7) | 3 (1.3) | 0.116 |
Vomiting | 53 (8.5) [6.6–11.0] | 44 (11.5) | 9 (3.8) | 0.010 |
Insomnia | 89 (14.3) [11.8–17.3] | 50 (13.1) | 39 (16.4) | 0.370 |
Chest burn | 35 (5.6) [4.1–7.8] | 20 (5.2) | 15 (6.3) | 0.562 |
Chest pain | 31 (5.0) [3.5–7.0] | 13 (3.4) | 18 (7.6) | 0.044 |
Abdominal pain | 157 (25.3) [22.0–28.9] | 102 (26.6) | 55 (23.1) | 0.620 |
Appetite loss | 149 (24.0) [20.8–27.5] | 104 (27.2) | 45 (18.9) | 0.028 |
Depression | 6 (1.0) [0.4–2.1] | 3 (0.8) | 3 (1.3) | 0.759 |
Anxiety | 20 (3.2) [2.1–4.9] | 7 (1.8) | 13 (5.5) | 0.014 |
Mental disorder | 2 (0.3) [0.1–1.3] | 2 (0.5) | 0 | NA |
Palpitation | 42 (6.8) [5.0–9.0] | 23 (6.0) | 19 (8.0) | 0.223 |
Jaundice | 1 (0.2) [0.0–1.1] | 1 (0.3) | 0 | NA |
Hiccups | 0 | 0 | 0 | NA |
Deafness | 4 (0.6) [0.2–1.7] | 1 (0.3) | 3 (1.3) | 0.218 |
Hearing loss | 3 (0.5) [0.2–1.5] | 1 (0.3) | 2 (0.8) | 0.350 |
Amenorrhea | 31 (7.3) [5.2–10.2] | 16 (6.3) | 15 (8.8) | 0.222 |
Erectile dysfunction | 6 (3.2) [1.4–7.0] | 1 (0.8) | 5 (7.8) | 0.047 |
*Within each cross-tabulation, because of missing data, the sum of the component cells may be less than the total number of attendances. Where a zero cell was reported in the cross-tabulation with fever, no p value is reported. NA, not applicable; Ref, reference category.
†All values are no. (%) [95% CI] unless indicated otherwise indicated.
‡All values are no. (%) unless otherwise indicated.
§p values are from univariate generalized estimating equations logistic regression analysis.
¶ Amenorrhea was recorded only for women (age range 15–40 years) and erectile dysfunction only for men (age range 24–35 years). Chest burn is a local term for heartburn.
Page created: December 14, 2016
Page updated: December 14, 2016
Page reviewed: December 14, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.